CN114306592A - 用于治疗患有高胆固醇血症的高心血管风险患者的方法 - Google Patents

用于治疗患有高胆固醇血症的高心血管风险患者的方法 Download PDF

Info

Publication number
CN114306592A
CN114306592A CN202111397525.XA CN202111397525A CN114306592A CN 114306592 A CN114306592 A CN 114306592A CN 202111397525 A CN202111397525 A CN 202111397525A CN 114306592 A CN114306592 A CN 114306592A
Authority
CN
China
Prior art keywords
patients
treatment
ldl
week
baseline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111397525.XA
Other languages
English (en)
Chinese (zh)
Inventor
C·阿诺汀
L·贝萨克
U·乔杜里
R·波尔迪
D·A·施韦默尔吉普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Publication of CN114306592A publication Critical patent/CN114306592A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202111397525.XA 2014-07-16 2015-07-16 用于治疗患有高胆固醇血症的高心血管风险患者的方法 Pending CN114306592A (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201462025371P 2014-07-16 2014-07-16
US62/025,371 2014-07-16
US201462043167P 2014-08-28 2014-08-28
US62/043,167 2014-08-28
US201462080725P 2014-11-17 2014-11-17
US62/080,725 2014-11-17
US201562132709P 2015-03-13 2015-03-13
US62/132,709 2015-03-13
EP15305830.0 2015-05-29
EP15305830 2015-05-29
CN201580049703.6A CN107106678A (zh) 2014-07-16 2015-07-16 用于治疗患有高胆固醇血症的高心血管风险患者的方法
PCT/US2015/040765 WO2016011260A1 (en) 2014-07-16 2015-07-16 Methods for treating high cardiovascular risk patients with hypercholesterolemia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580049703.6A Division CN107106678A (zh) 2014-07-16 2015-07-16 用于治疗患有高胆固醇血症的高心血管风险患者的方法

Publications (1)

Publication Number Publication Date
CN114306592A true CN114306592A (zh) 2022-04-12

Family

ID=53365943

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111397525.XA Pending CN114306592A (zh) 2014-07-16 2015-07-16 用于治疗患有高胆固醇血症的高心血管风险患者的方法
CN201580049703.6A Pending CN107106678A (zh) 2014-07-16 2015-07-16 用于治疗患有高胆固醇血症的高心血管风险患者的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580049703.6A Pending CN107106678A (zh) 2014-07-16 2015-07-16 用于治疗患有高胆固醇血症的高心血管风险患者的方法

Country Status (12)

Country Link
US (2) US20160137746A1 (enExample)
EP (2) EP3169362B1 (enExample)
JP (1) JP6912374B2 (enExample)
KR (3) KR20230007538A (enExample)
CN (2) CN114306592A (enExample)
AU (1) AU2015289617B2 (enExample)
CA (1) CA2955304C (enExample)
MX (2) MX378872B (enExample)
PL (1) PL3169362T3 (enExample)
RU (1) RU2723018C2 (enExample)
WO (1) WO2016011260A1 (enExample)
ZA (1) ZA201700196B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
BR112013018740A2 (pt) 2011-01-28 2019-01-08 Sanofi Sa anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CN103930444B (zh) 2011-09-16 2020-08-04 瑞泽恩制药公司 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW202021614A (zh) 2013-06-07 2020-06-16 法商賽諾菲生物技術公司 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
WO2016046684A1 (en) * 2014-09-23 2016-03-31 Pfizer Inc. Treatment with anti-pcsk9 antibodies
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
KR102456731B1 (ko) 2016-03-03 2022-10-24 리제너론 파아마슈티컬스, 인크. Pcsk9 억제제를 angptl3 억제제와 병용하여 투여함으로써 고지혈증을 갖는 환자를 치료하기 위한 방법
TW202310872A (zh) * 2017-06-09 2023-03-16 法商賽諾菲生物技術公司 藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法
AU2019231703A1 (en) * 2018-03-06 2020-10-22 Regeneron Pharmaceuticals, Inc. Use of PCSK9 inhibitor for reducing cardiovascular risk
RS66416B1 (sr) 2019-01-18 2025-02-28 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
BR112022009587A2 (pt) * 2019-11-18 2022-08-02 Ad Pharmaceuticals Co Ltd Anticorpo anti-pcsk9 e uso do mesmo
JP2023538522A (ja) * 2020-08-07 2023-09-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａｎｇｐｔｌ３阻害剤を伴う難治性高コレステロール血症を処置するための方法
CN116983434B (zh) * 2023-09-28 2024-03-15 康霖生物科技（杭州）有限公司 用于基因治疗的核酸构建体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
BR112013018740A2 (pt) * 2011-01-28 2019-01-08 Sanofi Sa anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20130006482A1 (en) * 2011-06-30 2013-01-03 Ramadev Burigsay Hukkeri Guidance system for a mobile machine
CN103930444B (zh) * 2011-09-16 2020-08-04 瑞泽恩制药公司 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
EP2706070A1 (en) * 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
CN114642661A (zh) * 2014-03-17 2022-06-21 赛诺菲生物技术公司 用于降低心血管风险的方法

Also Published As

Publication number Publication date
JP6912374B2 (ja) 2021-08-04
AU2015289617A1 (en) 2017-02-02
MX2017000628A (es) 2017-04-27
EP3169362B1 (en) 2020-06-10
KR102482375B1 (ko) 2022-12-29
EP3169362A1 (en) 2017-05-24
AU2015289617B2 (en) 2021-04-15
KR20230007538A (ko) 2023-01-12
CA2955304C (en) 2023-12-12
EP3753575A1 (en) 2020-12-23
MX2021000289A (es) 2021-03-31
PL3169362T3 (pl) 2020-12-28
WO2016011260A1 (en) 2016-01-21
CA2955304A1 (en) 2016-01-21
RU2017104799A (ru) 2018-08-16
KR20170028441A (ko) 2017-03-13
US20200255544A1 (en) 2020-08-13
ZA201700196B (en) 2024-09-25
RU2723018C2 (ru) 2020-06-08
CN107106678A (zh) 2017-08-29
US20160137746A1 (en) 2016-05-19
RU2017104799A3 (enExample) 2019-02-19
KR20240132123A (ko) 2024-09-02
MX378872B (es) 2025-03-11
JP2017522316A (ja) 2017-08-10

Similar Documents

Publication Publication Date Title
CN114306592A (zh) 用于治疗患有高胆固醇血症的高心血管风险患者的方法
JP2024147744A (ja) 心血管リスクを低減させる方法
TWI669131B (zh) Ｐｃｓｋ９抑制劑用於治療高血脂症的用途
RU2735521C2 (ru) Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh)
TW201945401A (zh) 降低心血管風險的方法
CN106029096A (zh) 用于治疗具有未被中等剂量他汀疗法充分控制的高胆固醇血症的患者的方法
CN115066272A (zh) Pcsk9抑制剂治疗纯合家族性高胆固醇血症的用途
JP2020143156A (ja) 心血管リスクを低減させる方法
HK40114248A (en) Methods for reducing cardiovascular risk
HK1236135B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
HK1236135A1 (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
HK1232890B (en) Methods for reducing cardiovascular risk
HK1232890A1 (en) Methods for reducing cardiovascular risk

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination